ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2021
Invasive group B Streptococcus among non-pregnant adults in Brussels-Capital Region, 2005-2019.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Global trends in macrolide and lincosamide resistance in Streptococcus species: a comprehensive systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Global patterns of antibiotic resistance in group BFrontiers in microbiology · 2025Pooled it
- Clinical Characteristics and Mortality Predictors of Group B Streptococcus Bacteremia in Adults: A Multicenter Retrospective Cohort Study in Japan, 2015-2024.Open forum infectious diseases · 2026Article
- Descriptive review: global spectrum of invasive group B streptococcal disease in nonpregnant adults: epidemiology, risk factors and clinical presentations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Clinical and Epidemiological Landscape of Antimicrobial Resistance and Virulence inAntibiotics (Basel, Switzerland) · 2026Review
- Type 2 diabetes mellitus exacerbates vaginal group BmSphere · 2026Article
- Molecular Epidemiology and Antimicrobial Resistance of Group BInfection and drug resistance · 2026Article
- Capsule typing and clonal relationships of group B streptococci isolated from male patients diagnosed with urinary tract infection.Folia microbiologica · 2025Article
- A retrospective review of group B streptococcus bacteraemia in Western Sydney, Australia from 2011-2023.IJID regions · 2025Article
- Identification and antimicrobial susceptibility testing ofIranian journal of microbiology · 2025Article
- Serotype distribution and clinical characteristics of Group B Streptococcus Bacteremia in nonpregnant adults: a 15-Year Multicenter Study in Korea.BMC infectious diseases · 2024Article
- Incidence of invasive infections with Group B streptococcus in adults in Norway 1996-2019: a nationwide registry-based case-control study.Infection · 2024Article
- Group B Streptococcus Infections in Non-Pregnant Adults, Italy, 2015-2019.Pathogens (Basel, Switzerland) · 2024Article
- Emergence of High-Level Gentamicin Resistance inAntibiotics (Basel, Switzerland) · 2024Article
- Neonatal Group B Streptococcus Disease.Pediatrics in review · 2024Review
- Article
- Recurrent Infective Endocarditis in an Adolescent due toOman medical journal · 2023Article
- CD1 and iNKT cells mediate immune responses against the GBS hemolytic lipid toxin induced by a non-toxic analog.PLoS pathogens · 2023Article
- Interspecies Interactions within the Host: the Social Network of Group BInfection and immunity · 2023Review
- Molecular characteristics and antibiotic resistance mechanisms of clindamycin-resistantFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess the incidence, clinical, microbiological features and outcome of invasive Streptococcus agalactiae (GBS) infections in non-pregnant adults in three tertiary hospitals of the Brussels-Capital Region. All bacterial cultures positive for GBS, from 2005 to 2019 from 3 hospitals of the Brussels-Capital Region, were extracted, and only cases of invasive diseases were included. Medical files were retrospectively retrieved for risk factors, clinical manifestations and outcome and also antibiotic-susceptibility testing and GBS serotypes. Incidence rates were calculated based on the hospitals catchment populations. A total of 337 cases of GBS-invasive infections were included. The incidence of invasive GBS for the 3 hospitals increased from 3.7 to 8.2 cases per 100.000 inhabitants between 2009 and 2018 (p = 0.04). The most frequently identified risk factors were diabetes (36.8%), obesity (35.0%), cancer (21.7%), renal disease (20.8%), and advanced age (≥ 65 years; 47.2%). Isolated bacteremia (22%), osteoarticular infection (21.4%), abscesses (13.9%), and skin and soft tissue infections (18.4%) were the most frequent manifestations. Intensive care unit admission was required in 21.7% and overall mortality was 9.4%. All strains remained susceptible to penicillin over the years. Up to 20% of strains were resistant to clindamycin. Serotypes Ia, Ib, II, III, IV, and V represented 96.8% of the available serotypes (60/62). As reported in several countries, invasive GBS disease in non-pregnant adults represents an increasing burden, particularly among diabetic, obese, and elderly patients. Almost all serotypes identified are included in the upcoming hexavalent GBS conjugate vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.